CagriSema misses its own 25 percent target and the market notices
The amylin plus semaglutide combination produced large weight loss in REDEFINE 1, but fell short of the figure the company had signalled to investors.
BAGSVÆRD, Denmark · Novo Nordisk company announcement (REDEFINE 1 topline)
22.7%